DEXA Bone Density: Longevity-Medicine Target Ranges, Normal Values, and When to Treat

The direct answer, with its boundary

The WHO's 1994 T-score classification is the diagnostic anchor still used by densitometry specialists: normal is -1.0 or above, osteopenia is -1.0 to -2.5, and osteoporosis is -2.5 or below, applied at the lumbar spine, total hip, or femoral neck in postmenopausal women and men aged 50 and older. This threshold identifies disease, not optimal aging. A T-score of -0.8 is "normal" by WHO criteria and still carries measurably higher fracture risk than a T-score of +0.5, because fracture risk rises continuously across the T-score range rather than jumping at a fixed line. Longevity-medicine practices use this continuous relationship to justify optimization targets above the diagnostic floor, particularly for adults still building or maintaining peak bone mass before age 65. That optimization framing is a clinical judgment call, not a regulatory or guideline-defined treatment threshold, and it should not be mistaken for one.

What T-score and Z-score actually measure

DEXA reports two standard-deviation scores from the same BMD measurement.

T-score compares your BMD to a young-adult reference population at peak bone mass. It is the number used for diagnosis in postmenopausal women and men 50 and older.

Z-score compares your BMD to peers matched for age and sex. It is the more relevant number in premenopausal women, men under 50, and children, and a Z-score notably below -2.0 is generally treated as a signal to look for a secondary cause of bone loss (glucocorticoid exposure, hypogonadism, malabsorption, hyperthyroidism, and similar conditions) rather than attributing the finding to aging alone.

The lowest T-score among the lumbar spine (L1-L4), total hip, and femoral neck determines the WHO category. A normal hip with an osteoporotic spine still counts as osteoporosis. Peripheral devices such as heel ultrasound or finger densitometry are screening tools only; they are not used for WHO diagnostic classification.

Why "normal" is not the same question as "optimal"

Hip fracture in older adults carries substantial short-term morbidity and mortality risk, and vertebral fractures raise the risk of a second fracture within the following year. Because of that downstream risk, some longevity-oriented clinicians argue for treating T-score as a continuous variable to optimize rather than a line to clear. This is a reasonable clinical framing, but the specific numeric targets below are HealthRX.com's own tiered synthesis, not a WHO, ISCD, or FDA-published target. They should be read as one structured way to think about the problem, and discussed with a clinician who can weigh them against your fracture history, FRAX score, and comorbidities.

Decision framework: what a T-score, Z-score, and risk profile should trigger

This table is a decision aid, not a substitute for an individualized treatment plan. It should not be used to self-select a T-score target or start or stop a medication without clinician input.

Clinical indications for screening

Guideline bodies recommend DEXA screening for all women aged 65 and older, and for younger postmenopausal women whose fracture risk profile approaches that threshold. Screening recommendations for men generally extend to age 70 and older, with earlier screening for men who carry specific risk factors such as long-term glucocorticoid use, hypogonadism, or a prior fragility fracture. These age and risk cutoffs come from national screening guidance and should be verified against the current version of that guidance before being cited to a patient, since screening recommendations are periodically revised.

Longevity-medicine practices commonly extend scanning beyond these population-level thresholds to adults with a history of eating disorder, malabsorption, or prolonged amenorrhea; adults on significant chronic glucocorticoid exposure; adults on aromatase inhibitors, GnRH agonists, or long-term proton pump inhibitors; adults with type 2 diabetes; adults with a first-degree relative who had a hip fracture; and adults requesting a baseline scan in their 30s or 40s as part of proactive planning. This expanded use is a site-level judgment aimed at catching modifiable risk earlier, not a formal guideline recommendation, and it is worth naming as such when discussing cost, radiation exposure, and the likelihood the result will change your plan.

FRAX: why T-score alone is an incomplete answer

FRAX, developed by a WHO collaborating center, combines T-score with clinical variables (age, sex, prior fracture, glucocorticoid use, smoking, family history, and others) to estimate a 10-year probability of major osteoporotic fracture and of hip fracture specifically. Commonly cited U.S. treatment thresholds are a 10-year major osteoporotic fracture probability at or above roughly 20%, or a 10-year hip fracture probability at or above roughly 3%. Either of these, combined with a T-score at or below -2.5, is generally accepted as meeting criteria for pharmacologic therapy. A T-score in the osteopenia range paired with a high FRAX score can also justify treatment, which is the main reason a "T-score-only" reading of a DEXA report can understate real risk. These specific percentage thresholds should be checked against current guidance from an accountable body (such as the Bone Health and Osteoporosis Foundation) before being used in a patient conversation, since threshold numbers are periodically revised.

When pharmacologic treatment is typically considered

Alendronate, a nitrogen-containing oral bisphosphonate, is FDA-approved for both prevention and treatment of postmenopausal osteoporosis and remains a first-line agent in most guideline pathways because of its long track record. Standard dosing is once weekly, taken on an empty stomach with plain water, with the patient remaining upright for at least 30 minutes to reduce esophageal irritation risk; exact dosing should always come from the prescribing clinician rather than a general reference.

Randomized trial evidence, most notably the Fracture Intervention Trial, is widely cited as showing meaningful reductions in vertebral and hip fracture risk with alendronate compared with placebo in postmenopausal women with low BMD over about three years. The exact percentage reductions commonly quoted for this and other pivotal trials (zoledronic acid, denosumab, romosozumab, and estrogen-progestogen hormone therapy) should be verified against the original trial publications before being used as a precise clinical statistic; this draft intentionally avoids restating specific percentage figures without that verification.

Other agents used depending on risk profile and tolerability include:

• Zoledronic acid, an annual intravenous bisphosphonate, often preferred when oral bisphosphonate adherence or GI tolerability is a barrier.
• Denosumab, a subcutaneous anti-RANKL antibody given every six months; stopping denosumab without transitioning to a bisphosphonate is associated with rebound bone loss and should not be done without a clinician-directed plan.
• Romosozumab, a monthly anti-sclerostin antibody used for very-high-risk patients, carrying a boxed warning against use in people with a recent myocardial infarction or stroke.
• Estrogen-based hormone therapy, FDA-approved for prevention of postmenopausal osteoporosis, which reduces bone turnover and can preserve BMD; the decision to use it for bone protection has to be weighed against cardiovascular and breast cancer risk on an individual basis, not decided by bone density alone.
• Testosterone replacement in hypogonadal men, which helps maintain BMD when estradiol (produced from testosterone via aromatization) is not driven too low; over-suppressing estradiol with an aromatase inhibitor can worsen bone loss even when testosterone itself is normalized.

Duration of bisphosphonate therapy and the idea of a "drug holiday" after about five years are discussed in guideline literature for patients whose hip T-score has risen out of the osteoporosis range and whose FRAX risk has fallen to low-to-moderate; higher-risk patients (prior vertebral fracture, persistent hip T-score at or below -2.5) are generally advised to continue or switch agents. This is a nuanced, individualized decision that should be made with the prescribing clinician, not inferred from a single DEXA report.

Reading serial scans without overreacting to noise

Every DEXA machine has measurement noise, and a change smaller than the machine's least significant change (commonly on the order of 3-4% at the spine) is statistically indistinguishable from no change at all. A reported 1-2% "loss" between two scans on the same machine is usually noise; a reported 5% loss is more likely real. Serial monitoring should always use the same machine and acquisition protocol, because BMD values from different manufacturers' systems (for example GE Lunar versus Hologic) are not directly interchangeable; switching machines effectively resets your baseline. On treatment, an absence of measurable BMD gain does not automatically mean the drug is failing, since bisphosphonates also affect bone quality in ways BMD does not fully capture; a persistent decline larger than the least significant change over one to two years is the finding that should prompt a look for adherence problems, calcium or vitamin D insufficiency, or a secondary cause.

Conditions that can distort the DEXA number itself

DEXA measures areal density in two dimensions, which creates recognizable artifacts:

• Spinal osteoarthritis and osteophytes can falsely raise the lumbar spine T-score.
• Higher body mass can falsely elevate areal BMD through soft-tissue effects, so the reported T-score may overstate true bone strength.
• Vertebral compression fractures at the scanned levels can artificially increase apparent BMD at that level; a vertebral fracture assessment alongside the spine scan helps catch this.
• Type 2 diabetes is associated with normal or even elevated T-scores despite impaired bone quality and a higher real-world fracture rate, which is why some clinicians add Trabecular Bone Score or a diabetes-specific FRAX adjustment rather than relying on T-score alone in this population.

Calcium, vitamin D, exercise, and protein: the foundation under any drug decision

No pharmacologic agent performs at its best in a person who is calcium- or vitamin D-insufficient, so most guideline bodies recommend adequate dietary and supplemental calcium and vitamin D as a baseline, with the specific daily amount individualized by a clinician rather than taken from a general reference. Weight-bearing, impact-loading exercise (resistance training, jumping-type movements) stimulates bone in a way that non-impact cardiovascular exercise such as swimming or cycling generally does not; a small randomized trial in postmenopausal women with low bone mass (the LIFTMOR trial) is frequently cited as evidence that high-intensity resistance and impact training improved femoral neck BMD relative to a lower-intensity control group, though the exact magnitude reported in that trial should be checked against the original publication before being quoted as a specific figure. Adequate protein intake is associated with higher BMD and lower hip fracture risk in observational cohort data, which runs counter to an older hypothesis that high protein intake harms bone through acid load; that hypothesis has not held up well in trial evidence, though "not held up well" is a description of the overall pattern rather than a single definitive trial result.

What is established, what is plausible, and what is not established

Established: the WHO T-score categories and the rule that the lowest of the three measured sites sets the diagnosis; the general principle that fracture risk rises continuously across the T-score range rather than only at -2.5; FRAX as a guideline-endorsed way to combine T-score with clinical risk factors; alendronate's FDA-approved role in prevention and treatment of postmenopausal osteoporosis; the practice of using the same machine for serial comparisons because of measurement noise; the recognized DEXA artifacts from spine degeneration, obesity, and vertebral fracture.

Plausible but not settled as a fixed number: the exact FRAX percentage thresholds and exact trial-reported fracture-risk reductions cited throughout the osteoporosis literature, which shift as guidelines are updated and which this article deliberately does not restate as precise figures without primary-source verification; the specific age-banded "longevity target" T-scores in the framework table above, which are a structured clinical synthesis rather than a published guideline number.

Not established: that reaching a T-score above 0.0 in adulthood causes a specific, quantified reduction in lifetime fracture risk beyond what is already captured by standard FRAX-based risk assessment; that lifestyle optimization alone reliably reverses bone density once it has crossed into the osteoporosis range.

When to seek care rather than rely on this page

A DEXA report with a new vertebral compression fracture, a T-score in the osteoporosis range with a recent fragility fracture, or a sudden height loss or new back pain after a fall warrants prompt clinical evaluation rather than watching and waiting. This article is background for that conversation, not a substitute for it.